

# May Cho

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5818426/publications.pdf>

Version: 2024-02-01

24  
papers

365  
citations

933264

10  
h-index

839398

18  
g-index

24  
all docs

24  
docs citations

24  
times ranked

868  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer. World Journal of Gastrointestinal Oncology, 2022, 14, 511-524.	0.8	1
2	Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer. Molecular and Clinical Oncology, 2022, 16, 100.	0.4	4
3	Wild-type <i>APC</i> Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer. Oncologist, 2021, 26, 208-214.	1.9	19
4	Immunotherapy Updates in Advanced Hepatocellular Carcinoma. Cancers, 2021, 13, 2164.	1.7	14
5	Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers. Current Colorectal Cancer Reports, 2021, 17, 55-68.	1.0	3
6	A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer. JAMA Network Open, 2021, 4, e2138432.	2.8	8
7	Effect and Safety of Radiation Therapy Boost to Extramesorectal Lymph Nodes in Rectal Cancer. Practical Radiation Oncology, 2020, 10, e372-e377.	1.1	7
8	Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2020, 21, 5232.	1.8	7
9	Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. Cancers, 2020, 12, 1168.	1.7	13
10	The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report. Frontiers in Oncology, 2020, 10, 581.	1.3	1
11	Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy. World Journal of Gastrointestinal Surgery, 2020, 12, 377-389.	0.8	3
12	Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. Clinical Colorectal Cancer, 2019, 18, 307-309.	1.0	6
13	Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers, 2019, 11, 841.	1.7	68
14	A Pilot Study of Vinorelbine Safety and Pharmacokinetics in Patients with Varying Degrees of Liver Dysfunction. Oncologist, 2019, 24, 1137-1145.	1.9	2
15	A single institution experience with palbociclib toxicity requiring dose modifications. Breast Cancer Research and Treatment, 2018, 168, 381-387.	1.1	29
16	Capecitabine-induced hypertriglyceridemia: a rare but clinically relevant treatment-related adverse event. Journal of Gastrointestinal Oncology, 2018, 9, 1213-1219.	0.6	8
17	Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clinical and Translational Medicine, 2018, 7, 32.	1.7	29
18	Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Oncotarget, 2017, 8, 42198-42213.	0.8	49

#	ARTICLE	IF	CITATIONS
19	A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres <sup>®</sup> versus SIR-Spheres <sup>®</sup> alone in chemotherapy-resistant colorectal cancer liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 608-613.	0.6	3
20	Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 314-323.	0.6	5
21	A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. <i>Oncotarget</i> , 2017, 8, 79750-79760.	0.8	12
22	RAS and BRAF in metastatic colorectal cancer management. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 687-704.	0.6	56
23	The state of regional therapy in the management of metastatic colorectal cancer to the liver. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 229-245.	1.1	5
24	Impact of <i>RAS</i> and <i>BRAF</i> mutations on carcinoembryonic antigen production and pattern of colorectal metastases. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 128.	0.8	13